Sputnik V Researchers Confirm Vaccine’s 91.4 Percent Effectiveness

Russia’s Sputnik V COVID-19 vaccine has shown 91.4 percent efficacy based on new data from an ongoing phase 3 trial.

Out of 78 confirmed infections among the 22,714 participants, 62 were in individuals who received a placebo, according to the Gamaleya Research Institute. No severe COVID-19 infections were found in participants who received the vaccine, while 20 severe cases were reported in the placebo group.

AstraZeneca announced last week it will launch a study evaluating a double-dose regimen of its COVID-19 candidate AZD1222 in combination with Sputnik V, which uses the same adenovirus-based technology.